The ability of CaSR agonists to reverse increased intestinal secretion and decreased absorption induced by bacterial enterotoxins, diminish overly active enteric nerve activity and motility, as well as restore compromised barrier function and imbalanced immune responses suggests that modulations of CaSR expression and activity using calcium mimetic or a combination of specific nutrients may provide a novel therapeutic approach for secretory diarrhea, IBS, and IBD. The gene discussed is CASR; the disease is irritable bowel syndrome.